Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1
Dan Zhu, Ruidan Xu, Xinping Huang, et al.
Cell Death and Differentiation (2020) Vol. 28, Iss. 6, pp. 1773-1789
Open Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 5, pp. 287-305
Closed Access | Times Cited: 331
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer
Zhenchuan Liu, Tingting Wang, Yunlang She, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 258
CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1
Dongbao Li, Yuhong Wang, Chao Dong, et al.
Oncogene (2022) Vol. 42, Iss. 2, pp. 83-98
Open Access | Times Cited: 163
Deubiquitinases in cancer
Grant Dewson, Pieter J.A. Eichhorn, David Komander
Nature reviews. Cancer (2023) Vol. 23, Iss. 12, pp. 842-862
Closed Access | Times Cited: 110
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
Yanan Qi, Zhu Liu, Lian‐Lian Hong, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 59
TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance
Xiaoxiao Ma, Shuqin Jia, Gangjian Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 44
Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1
W. Ren, Zilong Xu, Yating Chang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Recent Advances in Small Molecule Inhibitors of Deubiquitinating Enzymes
Pengwei Liu, Zhengyang Chen, Yiting Guo, et al.
European Journal of Medicinal Chemistry (2025), pp. 117324-117324
Closed Access | Times Cited: 4
Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1
Yizeng Fan, Weichao Dan, Yuzhao Wang, et al.
Cell Metabolism (2025)
Open Access | Times Cited: 3
The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
Zhiwei Fan, Changyue Wu, Miaomiao Chen, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 3, pp. 1041-1053
Open Access | Times Cited: 65
Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis
Xue Han, Chune Ren, Chao Lü, et al.
Cell Death and Differentiation (2022) Vol. 29, Iss. 9, pp. 1864-1873
Open Access | Times Cited: 60
Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
Jinrui Zhang, Ge Zhang, Wenjing Zhang, et al.
Cell Death and Differentiation (2022) Vol. 29, Iss. 11, pp. 2247-2261
Open Access | Times Cited: 51
OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer
Cheng Yan, Huijie Yang, Peng Su, et al.
Oncogene (2022) Vol. 41, Iss. 48, pp. 5186-5198
Open Access | Times Cited: 47
Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms
Jinhui Guo, Jie Zhao, Wen Fu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 45
New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials
Haoer Jin, Sha Qin, Jiang He, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 7, pp. 2775-2794
Open Access | Times Cited: 44
Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation
Chengyu Shi, Ying Wang, Minjie Wu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43
PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Changsheng Huang, Shengxiang Ren, Yaqi Chen, et al.
Science Advances (2023) Vol. 9, Iss. 21
Open Access | Times Cited: 35
Deubiquitylating Enzymes in Cancer and Immunity
Jiang Ren, Peng Yu, Sijia Liu, et al.
Advanced Science (2023) Vol. 10, Iss. 36
Open Access | Times Cited: 32
The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
Bo Hou, Ting Chen, He Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1
Zean Kuang, Xiaojia Liu, Na Zhang, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 10, pp. 2249-2264
Open Access | Times Cited: 26
PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination
Xinfang Yu, Wei Li, Haidan Liu, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 3
Open Access | Times Cited: 25
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Yazhen Wang, Zhou Yang, Lianyi Yang, et al.
Advanced Science (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 24
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Xiang Chen, Lingjuan Chen, Xiaofei Peng, et al.
Translational Oncology (2023) Vol. 40, pp. 101851-101851
Open Access | Times Cited: 24
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
Zheng-Zheng Yu, Yun-Ya Liu, Wei Zhu, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006345-e006345
Open Access | Times Cited: 23
EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer
Jiaqi Huang, Qianqian Yin, Yuqing Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 23
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top